Cellular Biomedicine Group, Inc.

Form 4

October 08, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

if no longer subject to Section 16.

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average

0.5

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

burden hours per response...

See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Cao Wei (William)

(Street)

(State)

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

Cellular Biomedicine Group, Inc.

(Check all applicable)

[CBMG]

(Last) (First) 3. Date of Earliest Transaction

X_ Officer (give title below)

10% Owner Other (specify

(Month/Day/Year)

08/26/2014

Chief Executive Officer

6. Individual or Joint/Group Filing(Check

530 UNIVERSITY AVENUE, #17

(Middle)

(Zip)

4. If Amendment, Date Original

Applicable Line)

_X__ Director

X Form filed by One Reporting Person

Filed(Month/Day/Year)

Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

PALO ALTO, CA 94301

(City)

		Table 1 - Non-Derivative Securities Acquired, Disposed of, or Deficientially Owned									
1.Title of	2. Transaction Date	2A. Deemed	3. 4. Securities Acquired			5. Amount of	6.	7. Nature of			
Security	(Month/Day/Year)	Execution Date, if	Transaction(A) or Disposed of				Securities	Ownership	Indirect		
(Instr. 3)		any	Code (D)			Beneficially	Form:	Beneficial			
		(Month/Day/Year)	(Instr. 8)	nstr. 8) (Instr. 3, 4 and 5)			Owned	Direct (D)	Ownership		
							Following	or Indirect	(Instr. 4)		
				(4)		Reported	(I)				
					(A)		Transaction(s)	(Instr. 4)			
			α 1 α	A	or	ъ.	(Instr. 3 and 4)				
			Code V	Amount	(D)	Price					
Common									By W and J		
	08/26/2014		<u>J(1)</u>	23,543	A	\$0	23,543	I	Development		
Stock									Ltd (2)		
									_		

Common Stock

D 222,518

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

1

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	f 2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Titl	le and	8. Price of	9. Nu
Derivative	e Conversion	(Month/Day/Year)	Execution Date, if	TransactionNumber		Expiration D	Expiration Date		ınt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	/Year)	Under	rlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e		Secur	ities	(Instr. 5)	Bene
	Derivative				Securities	S		(Instr.	. 3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									A		
									Amount		
						Date	Expiration	T:41-	or Namel		
						Exercisable	Date		Number		
				C-1- V	(A) (D)				of		
				Code v	(A) (D)				Shares		

Reporting Owners

Relationships Reporting Owner Name / Address

> Officer Other Director 10% Owner

Cao Wei (William)

530 UNIVERSITY AVENUE, #17 X Chief Executive Officer

PALO ALTO, CA 94301

Signatures

/s/ Wei

(William) Cao 10/08/2014

**Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Reporting Person received 23,543 shares of common stock, par value \$0.001 per share ("Common Stock"), of Cellular Biomedicine Group, Inc. from Global Health Investment Holdings Ltd. in a pro rata distribution to its members.
- Reporting Person jointly owns W and J Development Ltd. with his spouse. As such, the Reporting Person may be deemed to have an indirect pecuniary interest in the shares of Common Stock held directly by W and J Development Ltd.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2